FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019493508> ?p ?o ?g. }

• W2019493508 endingPage "1696" @default.
• W2019493508 startingPage "1686" @default.
• W2019493508 abstract "Background The 1-year results of the prospective register STELLA suggested that primary stenting of long femoropopliteal (FP) lesions (≥15-cm) was a sure and effective treatment. However, the long-term results of this technique remain unknown. Methods STELLA is a prospective monocentric register of patients treated for FP lesions ≥15-cm (Trans-Atlantic Inter-Society Consensus [TASC] C and D) by direct stenting (Flexstar®, Bard). The patients with de novo atheromatous lesions were included between November 2008 and October 2009 when the guidewire had crossed the lesion. Restenoses were excluded. The follow-up was coordinated by a clinical research assistant. Clinical and ultrasound evaluation were carried out every 3 months for 12 months, then every 6 months up to 30 months. Restenosis was defined by an index of peak systolic velocity >2.4. Results Among the 58 patients (62 limbs) included, 40.3% presented an effort ischemia and 59.7% a critical ischemia (CI). The mean age was 71 ± 12 years. The lesions were classified as TASC D in 37.1% of the cases. The median length of the stenting was 26 ± 18 cm. The average follow-up was 26.1 months (1–30). At 30 months, a complete follow-up was obtained in 55 patients (58 limbs). The rate of survival was 79.6%. Nine of the 11 patients deceased presented initially with CI. Death was in connection with CI in 2 cases. At the date of latest news, 98.3% of the patients were under antiaggregating treatment, 20% received antivitamin K treatment, 75% received statins, and 75% received angiotensin-converting-enzyme inhibitors. The rates of maintenance of the primary and secondary clinical improvement were 68.6 ± 6.0% and 82.6 ± 5.1% at 12 months and 65.1 ± 6.2% and 78.4 ± 5.6% at 30 months, respectively. The mean Rutherford index was 4.1 ± 1.0 in preoperative, 0.7 ± 1.2 at 12 months, and 0.6 ± 1.1 at 30 months (P < 0.001). Two major amputations were carried out at 9 and 28 months for patients initially with CI. The mean systolic pressure index was 0.6 ± 0.1 in preoperative and 1.0 ± 0.2 at 1-year and 0.9 ± 0.3 at 30 months (P < 0.001). The rates of primary and secondary patency were 66 ± 6.3% and 80.9 ± 9.5% at 12 months and 62.2 ± 6.6% and 77.2 ± 5.9% at 30 months, respectively. Between 0 and 12 months, 12 (19.3%) intrastent restenosis (ISR) were noted. One ISR was observed after 12 months. At the same period, we observed 11 and 1 target lesion revascularization, respectively. Conclusions In the long run, the primary stenting of long FP lesions (≥15-cm) is a safe and durable treatment. A strong clinical and ultrasound monitoring is indicated during the first year to maintain the clinical improvement. The 1-year results of the prospective register STELLA suggested that primary stenting of long femoropopliteal (FP) lesions (≥15-cm) was a sure and effective treatment. However, the long-term results of this technique remain unknown. STELLA is a prospective monocentric register of patients treated for FP lesions ≥15-cm (Trans-Atlantic Inter-Society Consensus [TASC] C and D) by direct stenting (Flexstar®, Bard). The patients with de novo atheromatous lesions were included between November 2008 and October 2009 when the guidewire had crossed the lesion. Restenoses were excluded. The follow-up was coordinated by a clinical research assistant. Clinical and ultrasound evaluation were carried out every 3 months for 12 months, then every 6 months up to 30 months. Restenosis was defined by an index of peak systolic velocity >2.4. Among the 58 patients (62 limbs) included, 40.3% presented an effort ischemia and 59.7% a critical ischemia (CI). The mean age was 71 ± 12 years. The lesions were classified as TASC D in 37.1% of the cases. The median length of the stenting was 26 ± 18 cm. The average follow-up was 26.1 months (1–30). At 30 months, a complete follow-up was obtained in 55 patients (58 limbs). The rate of survival was 79.6%. Nine of the 11 patients deceased presented initially with CI. Death was in connection with CI in 2 cases. At the date of latest news, 98.3% of the patients were under antiaggregating treatment, 20% received antivitamin K treatment, 75% received statins, and 75% received angiotensin-converting-enzyme inhibitors. The rates of maintenance of the primary and secondary clinical improvement were 68.6 ± 6.0% and 82.6 ± 5.1% at 12 months and 65.1 ± 6.2% and 78.4 ± 5.6% at 30 months, respectively. The mean Rutherford index was 4.1 ± 1.0 in preoperative, 0.7 ± 1.2 at 12 months, and 0.6 ± 1.1 at 30 months (P < 0.001). Two major amputations were carried out at 9 and 28 months for patients initially with CI. The mean systolic pressure index was 0.6 ± 0.1 in preoperative and 1.0 ± 0.2 at 1-year and 0.9 ± 0.3 at 30 months (P < 0.001). The rates of primary and secondary patency were 66 ± 6.3% and 80.9 ± 9.5% at 12 months and 62.2 ± 6.6% and 77.2 ± 5.9% at 30 months, respectively. Between 0 and 12 months, 12 (19.3%) intrastent restenosis (ISR) were noted. One ISR was observed after 12 months. At the same period, we observed 11 and 1 target lesion revascularization, respectively. In the long run, the primary stenting of long FP lesions (≥15-cm) is a safe and durable treatment. A strong clinical and ultrasound monitoring is indicated during the first year to maintain the clinical improvement." @default.
• W2019493508 created "2016-06-24" @default.
• W2019493508 creator A5011949056 @default.
• W2019493508 creator A5019626709 @default.
• W2019493508 creator A5033836897 @default.
• W2019493508 creator A5042251533 @default.
• W2019493508 creator A5061531943 @default.
• W2019493508 creator A5076324806 @default.
• W2019493508 creator A5084322979 @default.
• W2019493508 date "2014-10-01" @default.
• W2019493508 modified "2023-10-05" @default.
• W2019493508 title "Primary Stenting of TASC C and D Femoropopliteal Lesions: Results of the STELLA Register at 30 Months" @default.
• W2019493508 cites W114852567 @default.
• W2019493508 cites W1969838166 @default.
• W2019493508 cites W1985057368 @default.
• W2019493508 cites W1988902767 @default.
• W2019493508 cites W1993138536 @default.
• W2019493508 cites W2008508983 @default.
• W2019493508 cites W2008850799 @default.
• W2019493508 cites W2012092298 @default.
• W2019493508 cites W2035314553 @default.
• W2019493508 cites W2044672502 @default.
• W2019493508 cites W2062321446 @default.
• W2019493508 cites W2063973040 @default.
• W2019493508 cites W2068502485 @default.
• W2019493508 cites W2069424077 @default.
• W2019493508 cites W2081239089 @default.
• W2019493508 cites W2087146266 @default.
• W2019493508 cites W2106174706 @default.
• W2019493508 cites W2121525080 @default.
• W2019493508 cites W2125688923 @default.
• W2019493508 cites W2132880199 @default.
• W2019493508 cites W2140933942 @default.
• W2019493508 cites W2142450658 @default.
• W2019493508 cites W2145994607 @default.
• W2019493508 cites W2147137884 @default.
• W2019493508 cites W2159687453 @default.
• W2019493508 cites W2569906950 @default.
• W2019493508 cites W2887033821 @default.
• W2019493508 cites W2887208783 @default.
• W2019493508 cites W4236938366 @default.
• W2019493508 cites W2068671795 @default.
• W2019493508 doi "https://doi.org/10.1016/j.avsg.2014.03.033" @default.
• W2019493508 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24709402" @default.
• W2019493508 hasPublicationYear "2014" @default.
• W2019493508 type Work @default.
• W2019493508 sameAs 2019493508 @default.
• W2019493508 citedByCount "14" @default.
• W2019493508 countsByYear W20194935082014 @default.
• W2019493508 countsByYear W20194935082017 @default.
• W2019493508 countsByYear W20194935082020 @default.
• W2019493508 countsByYear W20194935082021 @default.
• W2019493508 countsByYear W20194935082022 @default.
• W2019493508 countsByYear W20194935082023 @default.
• W2019493508 crossrefType "journal-article" @default.
• W2019493508 hasAuthorship W2019493508A5011949056 @default.
• W2019493508 hasAuthorship W2019493508A5019626709 @default.
• W2019493508 hasAuthorship W2019493508A5033836897 @default.
• W2019493508 hasAuthorship W2019493508A5042251533 @default.
• W2019493508 hasAuthorship W2019493508A5061531943 @default.
• W2019493508 hasAuthorship W2019493508A5076324806 @default.
• W2019493508 hasAuthorship W2019493508A5084322979 @default.
• W2019493508 hasConcept C126838900 @default.
• W2019493508 hasConcept C141071460 @default.
• W2019493508 hasConcept C188816634 @default.
• W2019493508 hasConcept C2778283817 @default.
• W2019493508 hasConcept C2778583881 @default.
• W2019493508 hasConcept C2781156865 @default.
• W2019493508 hasConcept C71924100 @default.
• W2019493508 hasConceptScore W2019493508C126838900 @default.
• W2019493508 hasConceptScore W2019493508C141071460 @default.
• W2019493508 hasConceptScore W2019493508C188816634 @default.
• W2019493508 hasConceptScore W2019493508C2778283817 @default.
• W2019493508 hasConceptScore W2019493508C2778583881 @default.
• W2019493508 hasConceptScore W2019493508C2781156865 @default.
• W2019493508 hasConceptScore W2019493508C71924100 @default.
• W2019493508 hasIssue "7" @default.
• W2019493508 hasLocation W20194935081 @default.
• W2019493508 hasLocation W20194935082 @default.
• W2019493508 hasOpenAccess W2019493508 @default.
• W2019493508 hasPrimaryLocation W20194935081 @default.
• W2019493508 hasRelatedWork W191295512 @default.
• W2019493508 hasRelatedWork W2094850049 @default.
• W2019493508 hasRelatedWork W2155387881 @default.
• W2019493508 hasRelatedWork W2169284134 @default.
• W2019493508 hasRelatedWork W2372001256 @default.
• W2019493508 hasRelatedWork W2416684306 @default.
• W2019493508 hasRelatedWork W2420793516 @default.
• W2019493508 hasRelatedWork W2461920925 @default.
• W2019493508 hasRelatedWork W2518840228 @default.
• W2019493508 hasRelatedWork W2962975514 @default.
• W2019493508 hasVolume "28" @default.
• W2019493508 isParatext "false" @default.
• W2019493508 isRetracted "false" @default.
• W2019493508 magId "2019493508" @default.
• W2019493508 workType "article" @default.